{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:33:47Z","timestamp":1775018027094,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006087","name":"National Autonomous University of Mexico Directorate General of Academic Staff Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126814","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T16:11:00Z","timestamp":1738426260000},"page":"126814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Antitumoral effectiveness and safety of intravenous versus subcutaneous administration of immunomodulatory peptide GK-1 in a murine breast cancer model"],"prefix":"10.1016","volume":"50","author":[{"given":"Juan A.","family":"Hern\u00e1ndez-Aceves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelynne","family":"Cervantes-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Cruz-Gregorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Karina","family":"Aranda-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Moctezuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Pe\u00f1a-Agudelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osiris J.","family":"Pati\u00f1o-Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisela","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Sifontes-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonathiu","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Pedraza-Chaverri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edda","family":"Sciutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladis","family":"Fragoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126814_bb0005","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives (review)","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126814_bb0015","first-page":"15","article-title":"Treatment strategies against triple-negative breast Cancer: an updated review","volume":"14","author":"Maqbool","year":"2022","journal-title":"Breast Cancer\u00a0: Targets Therapy"},{"key":"10.1016\/j.vaccine.2025.126814_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.molimm.2020.09.015","article-title":"Helminth-derived peptide GK-1 induces Myd88-dependent pro-inflammatory signaling events in bone marrow-derived antigen-presenting cells","volume":"128","author":"Montero","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.imlet.2018.10.010","article-title":"Impact of the GK-1 adjuvant on peritoneal macrophages gene expression and phagocytosis","volume":"201","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2025.126814_bb0030","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1007\/s00262-023-03538-9","article-title":"GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model","volume":"72","author":"Hern\u00e1ndez-Aceves","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2025.126814_bb0035","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1016\/j.vaccine.2017.08.060","article-title":"GK-1 peptide reduces tumor growth, decreases metastatic burden, and increases survival in a murine breast cancer model","volume":"35","author":"Torres-Garc\u00eda","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.126814_bb0040","first-page":"682","article-title":"The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model","volume":"28","author":"Perez-Torres","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.vaccine.2025.126814_bb0045","first-page":"682","article-title":"The synthetic parasite-derived peptide GK1 increases survival in a preclinical mouse melanoma model","volume":"28","author":"P\u00e9rez-Torres","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.vaccine.2025.126814_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.07.006","article-title":"The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1\/PD-L1 pathway","volume":"212","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0055","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/CVI.00106-09","article-title":"Towards identification of the mechanisms of action of parasite-derived peptide GK1 on the immunogenicity of an influenza vaccine","volume":"16","author":"Segura-Vel\u00e1zquez","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0060","article-title":"Clinical cancer immunotherapy: current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0065","first-page":"262","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antib Ther"},{"key":"10.1016\/j.vaccine.2025.126814_bb0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0169-409X(01)00154-5","article-title":"Liposomes to target the lymphatics by subcutaneous administration","volume":"50","author":"Oussoren","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2025.126814_bb0075","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2025.126814_bb0080","series-title":"Intravenous versus subcutaneous drug administration. Which Do Patients Prefer? A Systematic Review Patient","volume":"8","author":"Stoner","year":"2015"},{"key":"10.1016\/j.vaccine.2025.126814_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12919-021-00230-7","article-title":"Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert\u2019s and patient\u2019s perspective","volume":"15","author":"Jonaitis","year":"2021","journal-title":"BMC Proc"},{"key":"10.1016\/j.vaccine.2025.126814_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im2002s39","article-title":"Mouse 4T1 breast tumor model","volume":"39","author":"Pulaski","year":"2000","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0095","doi-asserted-by":"crossref","first-page":"A3.B.1","DOI":"10.1002\/0471142735.ima03bs111","article-title":"Trypan blue exclusion test of cell viability","volume":"111","author":"Strober","year":"2015","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0100","series-title":"The Lowry method for protein quantitation","author":"Waterborg","year":"2003"},{"key":"10.1016\/j.vaccine.2025.126814_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yexmp.2006.06.007","article-title":"Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors","volume":"82","author":"SA","year":"2007","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0110","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.vaccine.2025.126814_bb0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0023677219883319","article-title":"Defining body-weight reduction as a humane endpoint: a critical appraisal","volume":"54","author":"Talbot","year":"2020","journal-title":"Lab Anim"},{"key":"10.1016\/j.vaccine.2025.126814_bb0120","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/CVI.05030-11","article-title":"Heterologous prime-boost oral immunization with GK-1 peptide from Taenia crassiceps cysticerci induces protective immunity","volume":"18","author":"Fragoso","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0125","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/IAI.67.5.2522-2530.1999","article-title":"Towards a Taenia solium cysticercosis vaccine: an epitope shared by Taenia crassiceps and Taenia solium protects mice against experimental cysticercosis","volume":"67","author":"Toledo","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.126814_bb0130","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.3390\/cancers13194797","article-title":"Cardiac toxicity associated with Cancer immunotherapy and biological drugs","volume":"13","author":"Montisci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vaccine.2025.126814_bb0135","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.3390\/cancers14174086","article-title":"Adverse renal effects of anticancer immunotherapy: a review","volume":"14","author":"Bor\u00f3wka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vaccine.2025.126814_bb0140","article-title":"GK-1 induces oxidative stress, mitochondrial dysfunction, decreased membrane potential, and impaired autophagy flux in a mouse model of breast Cancer","volume":"12","author":"Cruz-Gregorio","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.vaccine.2025.126814_bb0145","first-page":"49","article-title":"Novel treatment of melanoma: combined parasite-derived peptide GK-1 and anti-programmed death ligand 1 therapy","volume":"32","author":"Vera-Aguilera","year":"2017","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.vaccine.2025.126814_bb0150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in Cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0160","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/08923973.2019.1566359","article-title":"Preclinical evidences of safety of a new synthetic adjuvant to formulate with the influenza human vaccine: absence of subchronic toxicity and mutagenicity","volume":"41","author":"Cervantes-Torres","year":"2019","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.vaccine.2025.126814_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122686","article-title":"Role of anti-Cancer peptides as immunomodulatory agents: potential and design strategy","volume":"14","author":"Tripathi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vaccine.2025.126814_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/NAN.0b013e31824d2271","article-title":"Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs","volume":"35","author":"Dychter","year":"2012","journal-title":"J Infus Nurs"},{"key":"10.1016\/j.vaccine.2025.126814_bb0175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jconrel.2010.08.012","article-title":"Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems","volume":"147","author":"Mohanan","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2025.126814_bb0180","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ame2.12082","article-title":"The animal cachexia score (ACASCO)","volume":"2","author":"Betancourt","year":"2019","journal-title":"Animal Model Exp Med"},{"key":"10.1016\/j.vaccine.2025.126814_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The natriuretic peptide system in heart failure: diagnostic and therapeutic implications","volume":"227","author":"Kuwahara","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2025.126814_bb0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/00365510802150158","article-title":"Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease","volume":"241","author":"Devarajan","year":"2008","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"10.1016\/j.vaccine.2025.126814_bb0195","first-page":"64","article-title":"Kidney injury molecule 1 (KIM-1): a multifunctional glycoprotein and biological marker (review)","volume":"13","author":"Karmakova","year":"2021","journal-title":"Modern Technol Med"},{"key":"10.1016\/j.vaccine.2025.126814_bb0200","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/B978-0-12-404630-6.00055-5","article-title":"Biomarkers in drug safety evaluation","author":"Anad\u00f3n","year":"2014","journal-title":"Biomarkers Toxicol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25001112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:29:24Z","timestamp":1741793364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"alternative-id":["S0264410X25001112"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126814","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumoral effectiveness and safety of intravenous versus subcutaneous administration of immunomodulatory peptide GK-1 in a murine breast cancer model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126814"}}